How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol
Crossref DOI link: https://doi.org/10.1007/s13300-019-0620-8
Published Online: 2019-04-30
Published Print: 2019-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hinton, William
Feher, Michael D.
Munro, Neil
de Lusignan, Simon https://orcid.org/0000-0002-8553-2641
Funding for this research was provided by:
AstraZeneca UK Limited (QC6114)
Text and Data Mining valid from 2019-04-30
Version of Record valid from 2019-04-30
Article History
Received: 13 March 2019
First Online: 30 April 2019